The future of multiple sclerosis therapy

Pharmacological Research

Volumn 60, Issue 4, 2009, Pages 207-211

  Kieseier, Bernd C ^a   Wiendl, Heinz ^b   Hartung, Hans Peter ^a   Stüve, Olaf ^c,d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Immunomodulation; Immunosuppression; Injectables; Multiple sclerosis; Oral therapy

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; BG 00012; CLADRIBINE; FINGOLIMOD; FUMADERM; FUMARIC ACID; FUMARIC ACID ESTER; IMMUNOMODULATING AGENT; LAQUINIMOD; LEFLUNOMIDE; MONOCLONAL ANTIBODY; PEGINTERFERON; PEGINTERFERON BETA; PLACEBO; ROQUINIMEX; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BINDING AFFINITY; CLINICAL TRIAL; COMMON COLD; DEGENERATIVE DISEASE; DISEASE CONTROL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL TOXICITY; HAIRY CELL LEUKEMIA; HEART INFARCTION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NERVE INJURY; NEUROLOGIC DISEASE; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; RELAPSE; RETINA MACULA EDEMA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINUSITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CLADRIBINE; CROTONIC ACIDS; FUMARATES; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; QUINOLONES; SPHINGOSINE; TOLUIDINES;

EID: 69249202564     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.03.016     Document Type: Article

References (52)

1. Kieseier B.C., Wiendl H., Hemmer B., et al. Treatment and treatment trials in multiple sclerosis. Curr Opin Neurol 20 (2007) 286-293
2. Kieseier B.C., and Hartung H.P. Current disease-modifying therapies in multiple sclerosis. Semin Neurol 23 (2003) 133-146
3. Wiendl H., and Kieseier B.C. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 12 (2003) 689-712
4. Hohlfeld R., and Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 101 (2004) 14599-14606
5. Fox R.J., and Ransohoff R.M. New directions in MS therapeutics: vehicles of hope. Trends Immunol 25 (2004) 632-636
6. Wiendl H., and Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 72 March (11) (2009) 1008-1015
7. Osterberg L., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
8. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 340 (1992) 952-956
9. Sipe J.C. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 5 (2005) 721-727
10. Beutler E., Sipe J.C., Romine J.S., et al. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93 (1996) 1716-1720
11. Sipe J.C., Romine J.S., Koziol J.A., et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344 (1994) 9-13
12. Romine J.S., Sipe J.C., Koziol J.A., et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 111 (1999) 35-44
13. Sipe J.C., Romine J.S., Koziol J.A., et al. Development of cladribine treatment in multiple sclerosis. Mult Scler 1 (1996) 343-347
14. Filippi M., Rovaris M., Iannucci G., et al. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55 (2000) 1714-1718
15. Filippi M., Rovaris M., Rice G.P., et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 176 (2000) 42-44
16. Rice G.P., Filippi M., and Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54 (2000) 1145-1155
17. Korn T., Magnus T., Toyka K., et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol 76 (2004) 950-960
18. Nakajima A., Yamanaka H., and Kamatani N. Leflunomide: clinical effectiveness and mechanism of action. Clin Calcium 13 (2003) 771-775
19. Korn T., Toyka K., Hartung H.P., et al. Suppression of experimental autoimmune neuritis by leflunomide. Brain 124 (2001) 1791-1802
20. Smolen J.S., Emery P., Kalden J.R., et al. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol Suppl 71 (2004) 13-20
21. Merrill J.E., Hanak S., Pu S., et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 256 1 (2009) 89-103
22. O'Connor P.W., Li D., Freedman M.S., et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66 (2006) 894-900
23. Brunmark C., Runstrom A., Ohlsson L., et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 130 (2002) 163-172
24. Jonsson S., Andersson G., Fex T., et al. Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship. J Med Chem 47 (2004) 2075-2088
25. Runstrom A., Leanderson T., Ohlsson L., et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 173 (2006) 69-78
26. Yang J.S., Xu L.Y., Xiao B.G., et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 156 (2004) 3-9
27. Andersen O., Lycke J., Tollesson P.O., et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47 (1996) 895-900
28. Karussis D.M., Meiner Z., Lehmann D., et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47 (1996) 341-346
29. Polman C., Barkhof F., Sandberg-Wollheim M., et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 64 (2005) 987-991
30. Comi G., Pulizzi A., Rovaris M., et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371 9630 (2008 Jun 21) 2085-2092
31. Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 45 (2004) 991-997
32. Brinkmann V., Davis M.D., Heise C.E., et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277 (2002) 21453-21457
33. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 108 (2005) 308-319
34. Cyster J.G. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol 23 (2005) 127-159
35. Yopp A.C., Fu S., Honig S.M., et al. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 173 (2004) 855-865
36. Muller H., Hofer S., Kaneider N., et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol 35 (2005) 533-545
37. Budde K., Schmouder R.L., Brunkhorst R., et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13 (2002) 1073-1083
38. Fujino M., Funeshima N., Kitazawa Y., et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305 (2003) 70-77
39. Rausch M., Hiestand P., Foster C.A., et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 20 (2004) 16-24
40. Webb M., Tham C.S., Lin F.F., et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 153 (2004) 108-121
41. Kappos L., Antel J., Comi G., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355 (2006) 1124-1140
42. O'Connor P., Comi G., Montalban X., et al. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72 January (1) (2009) 73-79
43. Leypoldt F., Münchau A., Moeller F., et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 72 March (11) (2009) 1022-1024
44. Schimrigk K., Brune N., Hellwig K., et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 13 6 (2006) 604-610
45. Kappos L., Gold R., Miller D.H., et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. BG-12 Phase IIb Study Investigators. Lancet 372 October (9648) (2008) 1463-1472
46. Linker R., and Kieseier B.C. Innovative therapy with monoclonal antibodies in multiple sclerosis. Therap Adv Neurol Disord 1 (2008) 33-42
47. Paolillo A., Coles A.J., Molyneux P.D., et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53 September (4) (1999) 751-757
48. Coles A.J., Wing M.G., Molyneux P., et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46 September (3) (1999) 296-304
49. Coles A.J., Cox A., Le Page E., et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253 January (1) (2006) 98-108
50. CAMMS223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008 Oct 23;359(17):1786-801.
51. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8 January (1) (2009) 28-31
52. Mullen J.T., Vartanian T.K., and Atkins M.B. Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 358 February (6) (2008) 647-648